Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Paul Burstow

- PMLiVE

Eisai submits new drug application for subcutaneous Leqembi in Japan

LEQEMBI is a treatment for early Alzheimer’s disease

- PMLiVE

Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment

The MHRA approval for IV dosing comes following positive results from the global phase 3 trial

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug Leqembi shows continued benefit over four years

An estimated 13 million people in the US will be living with Alzheimer’s disease by 2050

Biogen Idec building

Biogen/Eisai’s Alzheimer’s disease drug Leqembi granted EC approval

The neurodegenerative disorder currently affects an estimated 6.9 million people in Europe

- PMLiVE

Roche and Oxford BioTherapeutics enter oncology partnership worth over $1bn

The companies will aim to discover new antibody-based therapeutics for cancer

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug approved by FDA for monthly maintenance dosing

The neurodegenerative disease affects almost seven million people in the US

Biogen Idec building

Biogen/Eisai announce FDA BLA acceptance for injectable Alzheimer’s drug

The injection process for subcutaneous Leqembi is expected to take an average of 15 seconds

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug lecanemab receives CHMP recommendation

The neurodegenerative disorder affects an estimated 6.9 million people in Europe

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug approved by MHRA but not recommended by NICE

The health technology assessment agency outlined that the drug's benefits are “too small” to justify its costs

- PMLiVE

Eisai and SEED enter molecular glue degrader partnership worth up to $1.5bn

The companies are aiming to develop candidates for multiple neurodegeneration and oncology targets

- PMLiVE

Innovative Trials Announces New Charity Partnerships

Innovative Trials, a global patient recruitment and retention company, has just announced GOSH Charity and Oliver Patch Project as their charity partners of the year

Innovative Trials

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug shows continued cognitive improvement in long-term study

Leqembi was granted traditional US approval last year to treat patients in the early stages of the disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links